相关实验视频

Updated: Jun 29, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

关于伦瓦提尼布营销后不良事件的新见解:利用FAERS数据库进行全面分析

Zhe Yu¹, Jing Luo¹, Hongshan Wei^1,2

¹Peking University Ditan Teaching Hospital, Beijing, 100015, China.

|March 25, 2024

概括

这项研究确定了与癌症药物伦瓦提尼布相关的新药不良反应 (ADR). 持续监测对于患者的安全性和伦瓦替尼治疗的有效管理至关重要.

科学领域:

药物监督药物监督药物监督
在瘤学瘤学.
药品安全药品安全

背景情况:

伦瓦提尼布是一种多向激酶抑制剂,用于细胞癌,甲状腺癌和肝细胞癌.
监测不良事件 (AE) 对于优化伦瓦提尼布治疗期间的患者安全至关重要.

研究的目的:

为了识别和监测与lenvatinib相关的不良事件 (AE).
提供基于证据的指导,以安全有效地使用伦瓦提尼布.

主要方法:

从2015年第一季度到2023年第一季度对FDA不良事件报告系统 (FAERS) 数据库的分析.
使用ROR,PRR,BCPNN和EBGM算法来检测安全信号的不成比例分析.
在26个器官系统中检查伦瓦提尼布诱导的不良药物反应 (ADRs).

主要成果:

15,193例确诊的lenvatinib作为主要的疑似药物,导致50,508个AE.
预期的副作用如腹,吐和食欲下降得到证实.
意想不到的重大不良反应包括间歇性肺病,肺胸炎,脑膜炎和边缘性脑炎.

结论:

检测到与伦瓦提尼布相关的新奇和不可预见的ADR信号.
这些发现有助于理解林瓦提尼布使用与ADR之间的复杂关系.
持续的药物监测对于及时识别和管理AE至关重要,提高了患者的安全.

关键词:

BCPNNBCPNNBCPNNBCPNNBCPNNBCPNNBCPNNBC 这是EBGM的EBGM.这就是PRRR.ROROR ROR 这是一个很好的例子.伦瓦提尼布 (Lenvatinib) 是一种药物.

更多相关视频

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

相关概念视频

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...